Featured Slider

Under the auspices of the Czech Presidency of the Council of the European Union and with support from MEP Ondřej Knotek, The European Academy of Neurology (EAN) gathered a range of stakeholders at the European Parliament in Brussels on Thursday, December 8 to give them a glimpse of EAN’s forthcoming research agenda.

Our paper of the month reports the results of the ENCHANTED 2/MT trial, performed in 44 Chinese hospitals to compare more intensive with less intensive blood pressure management after successful endovascular thrombectomy.

Our authors of the month compared the occurrence of stroke, utilisation of recanalisation procedures, and demographic parameters during the pandemic period with data from the preceding year.

Abstract submission for our next annual congress is now open! EAN Programme Committee Chair, Prof. Ulf Kallweit shares the details on this and other latest news about EAN 2023.

Our authors of the month report the results of a multicentre phase-3 clinical trial exploring efficacy and safety of Lecanemab in patients with early AD over a follow-up period of eighteen months.

Our authors of the month conducted a retrospective study of the potential association between COVID-19 and seizures or epilepsy in the six months after infection, using an electronic health records network of 81 million people.

EAN Scientific Committee Chair, Prof. Thomas Berger, provides a general update, including guideline prioritisation news, ongoing research projects and the forthcoming 2nd EAN Science School.

Our research paper of the month presents the results of the Endovascular Treatment for Acute Basilar-Artery Occlusion (ATTENTION) trial; a multicentre, prospective, randomised and open-label trial, conducted in 36 Chinese centres.

The authors of our Covid paper of the month conducted this cross sectional study in southern Germany involving people aged 18–65, confirming the existence of a considerable burden of self-reported post-acute symptom clusters

EAN Secretary General, Tony Marson, provides a general update on membership issues, including new membership benefits and the opening of this year's membership renewal period..

This month we have selected the guidelines dedicated to the invasive therapeutic pathways for Parkinson's disease, published jointly by the EAN and the Movement Disorder Society-European Section.

Our paper of the month for October investigates vestibular function in patients with dizziness, vertigo and postural symptoms following COVID-19 vaccination.

New EAN Education Committee Chair, Irena Rektorova, introduces herself with an overview of recent and upcoming EAN educational initiatives.

This month we have selected two phase-2 trials investigating α-synuclein-binding antibodies as potential disease-modifying treatment of Parkinson’s disease.

Our authors of the month for September conclude that people with Parkinson's Disease and parkinsonism showed a higher risk of SARS-CoV-2 infection throughout the first 15 months of the pandemic.